Arkolith/Insider Trading/MRNS/Form 4

Manning Martha E

SVP, GEN. COUNSEL & CORP. SEC.MARINUS PHARMACEUTICALS, INC. (MRNS) · full profile →Form 4 · filed Feb 11, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
2 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 11, 2025Disposed to issuer(D)48K$0.55$26K0
Feb 7, 2025Disposed to issuer(D)12K$0.55$7K48K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 11, 2025Disposed to issuer(D)58K—$00
Feb 11, 2025Disposed to issuer(D)49K—$00
Feb 11, 2025Disposed to issuer(D)75K—$00
Feb 11, 2025Disposed to issuer(D)98K—$00
Feb 11, 2025Disposed to issuer(D)74K—$00
Feb 11, 2025Disposed to issuer(D)58K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-011243) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML